Table 4.
DSS analysis of clinical/pathological/molecular features by Cox regression.
| HR 1 | CI | p | ||
|---|---|---|---|---|
| IDH1 G105G SNP | Present vs. Absent | 1.34 | 0.87–2.08 | 0.185 |
| Sex | M vs. F | 1.07 | 0.76–1.51 | 0.704 |
| Age | Linear | 1.01 | 0.99–1.03 | 0.056 |
| >55 vs. <55 | 1.31 | 0.87–1.97 | 0.189 | |
| MGMT promoter methylation status | <9% | 1 | ||
| 9–29% | 0.53 | 0.32–0.89 | 0.016 | |
| ≥30% | 0.43 | 0.28–0.64 | <0.001 | |
| Mitotic count | Linear | 1.00 | 0.98–1.02 | 0.858 |
| Tumor site | Hemispheric | 1 | ||
| Median line | 0.76 | 0.28–2.08 | 0.604 | |
| Cerebellar | 5.55 | 1.35–22.9 | 0.018 | |
| Main involved lobe | Frontal | 1 | ||
| Temporal | 0.57 | 0.34–0.95 | 0.030 | |
| Parietal | 0.74 | 0.36–1.51 | 0.411 | |
| Occipital | 0.97 | 0.63–1.49 | 0.876 | |
| No predominant lobe | 1.03 | 0.40–2.64 | 0.953 | |
| Number of involved lobes | 1 | 1 | ||
| 2 | 1.09 | 0.74–1.61 | 0.645 | |
| 3 | 2.28 | 1.31–4.00 | 0.004 | |
| Multifocal tumor | Yes vs. No | 2.25 | 1.38–3.66 | 0.001 |
| Surgery type | Biopsy | 1 | ||
| Partial | 0.88 | 0.53–1.46 | 0.623 | |
| Gross | 0.53 | 0.33–0.86 | 0.010 |
Significance threshold: p < 0.05 1 HR = Hazard Ratio, CI = Confidence Interval.